Overview

Full Product Details

9781118487471

Table of Contents

Reviews

Oz should invite LaMattina back on his show. Since LaMattina treats all concerns respectfully, Oz needn't worry about feeling devalued or distrusted. (Barron's, 5 May 2014) This is an honest book by an insider who believes in the basic good that the industry does. (The Quarterly Review of Biology, 1 September 2013) Summing Up: Recommended. General audiences. (Choice, 1 September 2013) For those more loosely associated or aspiring to work with in it, I particularly recommend this book as a balanced and informative read on the pressures the industry faces. It should also provide the basis for more reasoned argument and forewarn anyone else potentially ambushed by a TV show. (ChemMedChem, 19 July 2013) That said, the suggestions made by LaMattina for improvements in productivity and transparency are timely, and the book makes interesting if unexciting reading. (Chemistry & Industry, 1 June 2013) John LaMattina (ex-head of Pfizer's global R&D) has a new book out about the industry, called Devalued and Distrusted. He tells Pharmalot that he got the idea to write a sequel to his earlier book, Drug Truths, when he appeared on the Dr. Oz show. (In The Pipeline, 1 December 2012)

<p> John LaMattina (ex-head of Pfizer's global R&D) has a new book out about the industry, called Devalued and Distrusted. He tells Pharmalot that he got the idea to write a sequel to his earlier book, Drug Truths, when he appeared on the Dr. Oz show. ( In The Pipeline , 1 December 2012)<p>

Oz should invite LaMattina back on his show. SinceLaMattina treats all concerns respectfully, Oz needn t worryabout feeling devalued or distrusted. ( Barron's , 5May 2014) This is an honest book by an insider who believes in thebasic good that the industry does. ( The QuarterlyReview of Biology , 1 September 2013) Summing Up: Recommended. Generalaudiences. ( Choice , 1 September 2013) For those more loosely associated or aspiring to workwith in it, I particularly recommend this book as a balanced andinformative read on the pressures the industry faces. It shouldalso provide the basis for more reasoned argument and forewarnanyone else potentially ambushed by a TV show. ( ChemMedChem , 19 July 2013) That said, the suggestions made by LaMattina forimprovements in productivity and transparency are timely, and thebook makes interesting if unexciting reading. ( Chemistry & Industry , 1 June 2013) John LaMattina (ex-head of Pfizer's global R&D) has anew book out about the industry, called Devaluedand Distrusted. He tells Pharmalot that he got the idea to write a sequel to hisearlier book, DrugTruths, when he appeared on the Dr. Oz show. ( In The Pipeline , 1 December 2012)

Author Information

JOHN L. LaMATTINA, PHD, retired as president of Pfizer's Global Research and Development in 2007, where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous honors and awards, including an Honorary Doctor of Science from the University of New Hampshire. Currently a Senior Partner with PureTech Ventures, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D (Wiley).

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available